AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04529720 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Boostagen (TdaP BioNet)
Description: Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.
Study NCT04529720 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.
Study NCT02608489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol (Diquas)
Description: Diquafosol group used diquafosol 6 times a day during study period.
Study NCT02608489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate (Hyalein)
Description: Hyaluronate group used sodium hyaluronate 6 times a day during study period.
Study NCT03758820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavorial Cognitive Therapy (BCT)
Description: Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises.
Study NCT03816241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy
Study NCT03816241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
Study NCT01026909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aristospan 20mg
Description: Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
Study NCT03926065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Vegetables Served in 100% Portion Size
Description: Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
Study NCT03926065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Vegetables Served in 200% Portion Size
Description: Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
Study NCT03926065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Vegetables Served in 100% Portion Size
Description: Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
Study NCT03926065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Vegetables Served in 200% Portion Size
Description: Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
Study NCT01984424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin was supplied as over-encapsulated 20 mg tablets
Study NCT01984424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Atorvastatin
Description: Placebo matching to atorvastatin supplied as over-encapsulated tablets
Study NCT01984424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
Study NCT01984424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
Study NCT01984424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
Study NCT01984424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab supplied as single-use prefilled autoinjector/pen(s)
Study NCT04105972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: FDC tablet for oral administration.
Study NCT04105972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT04105972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono tablet for oral administration.
Study NCT04105972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Mono tablet for oral administration.
Study NCT03711864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM21 CAR-T cells
Description: fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
Study NCT00592319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: oral taking of Celebrex (100 mg, BID) for 9 months
Study NCT00592319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL
Description: once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
Study NCT00592319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser or microsurgery
Description: once-time surgery to remove laryngeal papilloma
Study NCT01422681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimally invasive extracorporeal carbon dioxide removal
Description: The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min).
Study NCT03029247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
Study NCT03029247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
Study NCT03436134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sessions of conventional apheresis
Description: Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study.
Study NCT03436134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sessions of news apheresis with double filtration
Description: Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient.
Study NCT01004250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
Study NCT01004250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
Study NCT01004250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
Study NCT02600988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000IU/day of Vitamine D
Description: Administration of a specified dose of Vitamine D
Study NCT02600988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5000IU/day of Vitamine D
Description: Administration of a specified dose of Vitamine D
Study NCT01317875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count
Study NCT04009005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic diet and lifestyle
Description: Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
Study NCT03712540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Oral administration 30 mg
Study NCT03712540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral administration 600 mg
Study NCT04280718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous administration of efgartigimod
Study NCT02415920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
Study NCT02415920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
Study NCT03103022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
Study NCT03103022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
Study NCT03836898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Presbyopic posterior chamber phakic intraocular lens IPCL
Description: Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
Study NCT02054312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Interpersonal Psychotherapy (FB-IPT)
Study NCT02054312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client Centered Therapy (CCT)
Study NCT01042899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving (TOPS)
Description: The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
Study NCT01042899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving--Teen Only (TOPS-TO)
Description: TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
Study NCT02338206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone
Study NCT01042899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Resources Comparison (IRC)
Description: Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
Study NCT01042899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Resources Comparison (IRC)
Description: Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
Study NCT02451501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKITA
Study NCT02451501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKITA
Study NCT02254421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
Study NCT02254421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match presatovir administered orally or via nasogastric tube
Study NCT02743286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent sit-to-stands
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study NCT02743286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking breaks
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study NCT02743286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand more
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study NCT01024959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCA3 Assay
Description: Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
Study NCT03558958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-188 NF
Description: Poloxamer administered daily via sc injection at 5 mg/Kg
Study NCT04392232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: • Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry.
Study NCT01973491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-MS-1467
Description: Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
Study NCT03379064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted Cognitive Behavior Therapy for IBS
Description: Culturally adapted Cognitive Behavior Therapy for IBS
Study NCT05817305 — intervention group
Intervention type: OTHER
Intervention: Medical history and functional evaluation
Description: During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
Study NCT05817305 — intervention group
Intervention type: OTHER
Intervention: Health education
Description: Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
Study NCT01863043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No aspiration of gastric contents
Description: Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
Study NCT01863043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine aspiration of gastric contents
Description: Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
Study NCT03350659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine single 5mg/day
Study NCT03350659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine single 18mg/day
Study NCT03301688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: To compare the different drug batch number with different process
Study NCT02193802 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam® COLON 2 and PillCam Crohn's capsules
Description: Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator.
Study NCT03376802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT03376802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT04375982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venepuncture
Description: Blood tube will be collected from standard venepuncture
Study NCT04375982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fingerstick
Description: Capillary blood will be collected by fingerstick
Study NCT01912781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 120947A contact lens disinfecting solution
Description: Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses